TIZIANA LIFE SCIENCES LTD Total Liabilities

Latest as of December 2024: €7.35 Million EUR ≈ $8.59 Million USD

TIZIANA LIFE SCIENCES LTD total liabilities. Based on the latest financial reports, TIZIANA LIFE SCIENCES LTD (0RP) has total liabilities worth €7.35 Million EUR (≈ $8.59 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See TIZIANA LIFE SCIENCES LTD working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Total Liabilities of TIZIANA LIFE SCIENCES LTD (2021–2024)

Total liabilities of TIZIANA LIFE SCIENCES LTD from 2021 to 2024. This chart illustrates how TIZIANA LIFE SCIENCES LTD's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of TIZIANA LIFE SCIENCES LTD to see how much of total assets are deployed in long-term investments.

TIZIANA LIFE SCIENCES LTD Competitors by Total Liabilities

The table below lists competitors of TIZIANA LIFE SCIENCES LTD ranked by their total liabilities.

Company Country Total Liabilities
Cystech Electronics Corp
TWO:6651
Taiwan NT$352.87 Million
Shinhan Seobu T&D REIT Co Ltd
KO:404990
Korea ₩741.43 Billion
Surya Toto Indonesia Tbk
JK:TOTO
Indonesia Rp910.67 Billion
Whitehawk Therapeutics, Inc.
NASDAQ:WHWK
USA $9.85 Million
Norcod As
OL:NCOD
Norway Nkr335.97 Million
Admiral Group PLC
LSE:ADM
UK GBX7.20 Billion
Can2 Termik AS
IS:CANTE
Turkey TL4.08 Billion
Allpark Empreendimentos Participações e Serviços S.A
SA:ALPK3
Brazil R$2.23 Billion

Liability Composition Analysis (2021–2024)

This chart breaks down TIZIANA LIFE SCIENCES LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is TIZIANA LIFE SCIENCES LTD's balance sheet.

Liquidity & Leverage Metrics

TIZIANA LIFE SCIENCES LTD Total Liabilities Ratios Explained

TIZIANA LIFE SCIENCES LTD total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.02 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.87 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.65 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how TIZIANA LIFE SCIENCES LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for TIZIANA LIFE SCIENCES LTD (2021–2024)

The table below shows the annual total liabilities of TIZIANA LIFE SCIENCES LTD from 2021 to 2024.

Year Total Liabilities Change
2024-12-31 €7.35 Million
≈ $8.59 Million
+10.53%
2023-12-31 €6.65 Million
≈ $7.77 Million
-3.74%
2022-12-31 €6.91 Million
≈ $8.07 Million
-8.48%
2021-12-31 €7.55 Million
≈ $8.82 Million
--

About TIZIANA LIFE SCIENCES LTD

F:0RP Germany Biotechnology
Market Cap
$141.34 Million
€120.90 Million EUR
Market Cap Rank
#17698 Global
#1659 in Germany
Share Price
€0.95
Change (1 day)
-2.56%
52-Week Range
€0.95 - €1.58
All Time High
€5.43
About

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more